Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal
Redwood City, Calif., April 7, 2026, 05:10 PDT Soleno Therapeutics yanked its European application for VIOKAT on Tuesday, just a day after striking a $2.9 billion cash deal to be acquired by Neurocrine Biosciences. That move halts a regulatory review Soleno had earlier projected might wrap up by mid-2026.